Effect of Atorvastatin on Serial Changesin Coronary Physiology andPlaque Parameters
- Author(s)
- Cheol Hyun Lee; Jongmin Hwang; In-Cheol Kim; Yun-Kyeong Cho; Hyoung-Seob Park; Hyuck-Jun Yoon; Hyungseop Kim; Seongwook Han; Seung-Ho Hur; Kwon-Bae Kim; Jin Young Kim; Jin-Wook Chung; Joo Myung Lee; Joon-Hyung Doh; Eun-Seok Shin; Bon-Kwon Koo; Chang-Wook Nam
- Keimyung Author(s)
- Lee, Cheol Hyun; Hwang, Jong Min; Kim, In Cheol; Park, Hyoung Seob; Yoon, Hyuck Jun; Kim, Hyung Seop; Han, Seong Wook; Hur, Seung Ho; Kim, Kwon Bae; Kim, Jin Young; Nam, Chang Wook
- Department
- Dept. of Internal Medicine (내과학)
Dept. of Radiology (영상의학)
- Journal Title
- JACC Asia
- Issued Date
- 2022
- Volume
- 2
- Issue
- 6
- Keyword
- CAD, coronary artery disease; CFR, coronary flow reserve; FFR, fractional flow reserve; IMR, index of microcirculatory resistance; IVUS, intravascular ultrasound; LDL-C, low-density lipoprotein cholesterol; LLT, lipid-lowering therapy; MLA, minimal lumen area; OR, odds ratio; PAV, percent atheroma volume; Pa, proximal aortic pressure; Pd, distal coronary pressure; TAV, total atheroma volume; Tmn, mean transit time; VH, virtual histology; fractional flow reserve; intermediate coronary artery disease; statin therapy
- Abstract
- Background:
The effects of statin on coronary physiology have not been well evaluated.
Objectives:
The authors performed this prospective study to investigate changes in coronary flow indexes and plaque parameters, and their associations with atorvastatin therapy in patients with coronary artery disease (CAD).
Methods:
Ninety-five patients with intermediate CAD who received atorvastatin therapy underwent comprehensive physiological assessments with fractional flow reserve (FFR), coronary flow reserve, index of microcirculatory resistance, and intravascular ultrasound at the index procedure, and underwent the same evaluations at 12-month follow-up. Optimal low-density lipoprotein cholesterol (LDL-C) was defined as LDL-C <70 mg/dL or ≥50% reduction from the baseline. The primary endpoint was a change in the FFR.
Results:
Baseline FFR, minimal lumen area, and percent atheroma volume (PAV) were 0.88 ± 0.05, 3.87 ± 1.28, 55.92 ± 7.30, respectively. During 12 months, the percent change in LDL-C was -33.2%, whereas FFR was unchanged (0.87 ± 0.06 at 12 months; P = 0.694). Vessel area, lumen area, and PAV were significantly decreased (all P values <0.05). The achieved LDL-C level and the change of PAV showed significant inverse correlations with the change in FFR. In patients with optimally modified LDL-C, the FFR had increased (0.87 ± 0.06 vs 0.89 ± 0.07; P = 0.014) and the PAV decreased (56.81 ± 6.44% vs 55.18 ± 8.19%; P = 0.031), whereas in all other patients, the FFR had decreased (0.88 ± 0.05 vs 0.86 ± 0.06; P = 0.025) and the PAV remained unchanged.
Conclusions:
In patients with CAD, atorvastatin did not change FFR despite a decrease in the PAV. However, in patients who achieved the optimal LDL-C target level with atorvastatin, the FFR had significantly increased with decrease of the PAV. (Effect of Atorvastatin on Fractional Flow Reserve in Coronary Artery Disease [FORTE]; NCT01946815).
- Authorize & License
-
- Files in This Item:
-
Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.